Better Health, Brighter Future
Timely, Broad and Sustainable access
We are committed to improving the lives of patients around the world, providing timely and sustainable access to our innovative medicines in as many countries as possible. We strive to reduce the obstacles to accessing medicines for patients and are guided by our tiered pricing approach to help us deliver life-changing treatments to as many patients as possible, as quickly as possible.
Our tiered pricing approach allows for adjustments in prices relative to a country’s economic stage and health system maturity. Countries are grouped into four tiers based on factors such as Gross Domestic Product (GDP), out-of-pocket expenditure and policies covering vaccinations, rare diseases and available health care resources per citizen. Our pricing principle better reflects market dynamics and the broader health care environment to support more patients gaining access to our innovative medicines worldwide.
Our Approach to Pricing
As a global biopharmaceutical company, providing access to medicines is a responsibility as well as a part of our business model, so we’ve created a practical framework to guide and structure the execution and evolution of our pricing strategies to achieve value-based health care, based on three pillars:
1. TIERED PRICING
allows for adjustments in price relative to a country’s economic stage and health system maturity to support as many patients as possible gaining access to our innovative medicines worldwide
allows for adjustments in price relative to a country’s economic stage and health system maturity to support as many patients as possible gaining access to our innovative medicines worldwide
2. VALUE-BASED PRICING
responds to payers’ and providers’ need to manage uncertainty around the real-world clinical performance and economic impact of our innovative medicines
responds to payers’ and providers’ need to manage uncertainty around the real-world clinical performance and economic impact of our innovative medicines
3. PATIENT ASSISTANCE PROGRAMS (PAPS)
to support patients who have difficulty accessing medicines to obtain our innovative and life-saving treatments. PAPs are a cornerstone of Takeda’s Access to Medicines strategy to increase sustainable access to our medicines for complex and rare diseases and build sustainable capacity across the patient journey, addressing accessibility barriers
The Takeda Pricing Principle
Optimal patient access encompasses the speed of access and the breadth of coverage at a price that leads to a sustained business.
Our Access to Medicines strategy, together with our “optimal patient access” philosophy, supports sustainable access to our medicines for as many patients as possible in as many countries as possible.
Value-based health care
The ability of patients to access innovative treatments is of paramount importance to the future health and prosperity of the global population. We support the move to transform health care systems to value-based models. We believe that value-based health care can help health systems deliver more benefits to patients and society.
“Value” is characterized by the specific outcomes achieved in the eyes of all stakeholders and particularly, patients. We believe prices for innovative products should be based on value as measured by outcomes. Value-based pricing requires partnerships and access to comprehensive health data to see whether the intended outcome for the patient from taking the medicine has been achieved. We believe information technology can be used in a responsible way to collect and analyze health data for this purpose and that, wherever possible, patients should be empowered with the tools, standards and protections to measure and share their outcomes. Our Value-Based Agreement approach responds to payers’ and
providers’ needs to manage uncertainty around the real-world clinical performance and economic impact of our innovative medicines. We engage in Health Technology Assessments (HTAs) from the early pipeline stage to consider all different needs as this can provide useful guidance for value-based contracts. HTAs provide benefit by assessing both the patient voice and the evidence that supports a new medicine while recognizing the needs and economics of providing life-transforming therapies. We will continue our efforts to tailor valuebased contracts to local needs to accelerate patient access and increase the number of patients who benefit from our innovation.
Learn More
Takeda's Position on Value-Based Healthcare
Priorities in Action in the 2021 Annual Integrated Report